Condition

Unresectable Solid Tumor clinical trials and research

• 12Clinical trials
• 9Countries

Newest Unresectable Solid Tumor clinical trials

All recruiting trials (12)

• Adding targeted GRID-style radiation to standard palliative therapy for unresectable solid tumors

  This study tests whether adding spatially fractionated radiation therapy to standard palliative radiation helps relieve symptoms in patients with unresectable solid tumors.

  Recruiting at 2 sites Mayo Clinic · Scottsdale, Arizona and 1 other locations · NCT07856394

• DS1025a: first-in-human test in advanced solid tumors

  This first-in-human trial tests DS1025a in adults with advanced, metastatic, or unresectable solid tumors to see if it is safe and tolerable and to look for early signs of activity.

  Recruiting at 3 sites Phase 1 Daiichi Sankyo · Kashiwa and 2 other locations · NCT07681882

• MSK-TCR5 in adults with advanced solid tumors that have KRAS/HRAS/NRAS G12D

  This study tests MSK-TCR5 to see if it is safe for adults with advanced solid tumors carrying a KRAS, HRAS, or NRAS G12D mutation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07638371

• RGT-490 for adults with PIK3CA-mutated advanced solid tumors

  This trial will test RGT-490, an oral medicine, in adults whose advanced solid tumors carry a PIK3CA mutation and have progressed after prior therapy.

  Recruiting at 6 sites Phase 1 Regor Pharmaceuticals Inc. · Los Angeles, California and 5 other locations · NCT07524322

• Treatment for adult patients with solid tumors that have a specific p53 mutation

  This study is testing a new treatment for adults with advanced solid tumors that have a specific p53 mutation to see if it is safe and effective.

  Recruiting at 21 sites Phase 1 Clasp Therapeutics, Inc. · Scottsdale, Arizona and 20 other locations · NCT06778863

• Combining Afatinib and Pemigatinib for Advanced Solid Tumors

  This study is testing a combination of two drugs, Afatinib and Pemigatinib, to see if they can safely help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06302621

• Evaluating FMC-376 for advanced solid tumors with KRAS G12C mutations

  This study is testing a new drug called FMC-376 to see if it can help people with advanced solid tumors that have a specific KRAS G12C mutation.

  Recruiting at 20 sites Phase 1/2 Frontier Medicines Corporation · La Jolla, California and 25 other locations · NCT06244771

• Comparing two treatments for colorectal liver metastases

  This study is testing whether a new treatment called irreversible electroporation works better than stereotactic body radiotherapy for people with hard-to-treat colorectal cancer that has spread to the liver.

  Recruiting Phase 2/3 Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT06185556

• Testing a new treatment for advanced cancer using a radiolabeled drug

  This study is testing a new drug for adults with advanced cancer who have run out of other treatment options to see if it is safe and how well it works.

  Recruiting at 2 sites Phase 1/2 Spago Nanomedical AB · Adelaide, South Australia and 1 other locations · NCT06184035

• Evaluating Avapritinib for Advanced Gastrointestinal Stromal Tumors

  This study is testing if Avapritinib can help people with advanced gastrointestinal stromal tumors feel better and improve their health in real-world situations.

  Recruiting First Affiliated Hospital, Sun Yat-Sen University · Guangzhou · NCT05464875

• Using Avapritinib for treating specific types of gastrointestinal stromal tumors

  This study is testing if Avapritinib can help people with hard-to-treat gastrointestinal stromal tumors that have specific gene mutations feel better and live longer.

  Recruiting First Affiliated Hospital, Sun Yat-Sen University · Guangzhou · NCT05461664

• Testing a new drug for advanced solid tumors and breast cancer with specific mutations

  This study is testing a new drug called RLY-2608 to see if it can help people with advanced solid tumors and breast cancer that have specific mutations.

  Recruiting at 36 sites Phase 1 Relay Therapeutics, Inc. · Tucson, Arizona and 36 other locations · NCT05216432

Related topics

Quick answers

How many Unresectable Solid Tumor clinical trials are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in United States (7 trials), Australia (3 trials), China (2 trials), South Korea (1 trial), Japan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 1/2: 2, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →